News | August 21, 2014

diaDexus Announces FDA Acceptance for Review of 510(k) Submission for PLAC Test for Lp-PLA2 Activity

August 21, 2014 — diaDexus announced it has received notice from the U.S. Food and Drug Administration (FDA) that an administrative acceptance review was conducted on the traditional 510(k) submission of the PLAC Test for Lp-PLA2 Activity, and it was found to contain all of the necessary information needed to proceed with the substantive review. The PLAC Test for Lp-PLA2 Activity is an enzyme assay for the quantitative determination of Lp-PLA2 (Lipoprotein-Associated Phospholipase A2) activity in human plasma and serum.

“We have been working closely with the FDA through the pre-submission process to determine a path forward to obtain U.S. clearance for the Activity Test, and we are pleased that we are now one step closer in the regulatory process,” said Emi Zychlinsky, Ph.D., chief technical officer of diaDexus. “We have been focused on adding the PLAC test for Lp-PLA2 Activity to our product offering as it is performed on high throughput clinical chemistry analyzers and is designed to improve productivity and increase value for all of our customers, both cardiovascular specialty laboratories and large clinical laboratories.”

Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker that is critical in the formation of rupture-prone plaque. When elevated, this enzyme indicates arterial inflammation, which is associated with increased risk for cardiovascular disease.

The PLAC Tests are simple blood tests that measure Lp-PLA2 levels in a patient’s blood. diaDexus has developed and commercialized two PLAC tests. The PLAC Test ELISA Kit is cleared by the FDA as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis and is commercially available in the United States. The PLAC Test for Lp-PLA2 Activity is CE marked and available in the European Union; this test has not been cleared by the FDA.

For more information: www.diadexus.com

Related Content

HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Philips released a new version of its iFR system that displays FFR readings as an overlay on live angiographic, angiogram images.

Philips released a new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions. The system is supposed to speed diagnostic decision making and help guide percutaneous revascularization procedures. 

Feature | FFR Catheters| July 31, 2017 | Dave Fornell
The gold standard for assessing the hemodynamic significance of coronary lesions to determine if they should be revas
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
Overlay Init